Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Toyota Motor Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Toyota Motor Corp trades at $176.77 (market cap $205.39B). The key difference: Toyota Motor Corp is far larger — about 25.5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Toyota Motor Corp pays a 3.59% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | TM | |
|---|---|---|
Market Cap | $8.04B | $205.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $248.29 |
52-Week Low | $241.71 | $166.50 |
Enterprise Value | $7.85B | $369.58B |
Dividend Yield | — | 3.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Toyota Motor trades at $174.75, down 0.96% with neutral technical signals. The stock shows attractive valuation metrics including a P/E of 9.58 and P/B of 0.84, trading below industry averages. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $4.00 exceeding the $3.11 estimate. The company's $3.6 billion Texas expansion signals strong growth commitment amid positive hybrid vehicle sales momentum.
Toyota presents a compelling value opportunity with strong fundamentals and consistent earnings performance. However, declining profit margins and increasing debt levels warrant monitoring. Analyst consensus leans neutral with 62.5% hold ratings, suggesting cautious optimism about the company's strategic investments and hybrid leadership position in the evolving automotive landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
